U.S. Markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
10.17+0.08 (+0.79%)
At close: 4:00PM EDT

10.17 0.00 (0.00%)
After hours: 4:39PM EDT

People also watch
VSTMEPZMCEMPRGLSCLRB

ChemoCentryx, Inc.

850 Maude Avenue
Mountain View, CA 94043
United States
650-210-2900
http://www.chemocentryx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees62

Key Executives

NameTitlePayExercisedAge
Dr. Thomas J. Schall Ph.D.Founder, Chairman, Chief Exec. Officer and Pres858.64kN/A58
Ms. Susan M. KanayaChief Financial & Admin. Officer, Exec. VP and Sec.597.52kN/A54
Dr. Petrus J. Bekker M.D., Ph.D.Chief Medical Officer555.51kN/A57
Dr. Markus J. Cappel Ph.D.Chief Bus. Officer and TreasurerN/AN/A56
Dr. Rajinder Singh Ph.D.Sr. VP of ResearchN/AN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.

Corporate Governance

ChemoCentryx, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.